Tarsus Pharmaceuticals (TARS)
NASDAQ:TARS
TARS Stock Chart & Stats
$73.81
$0.07(0.13%)
At close: 4:00 PM EST
$73.81
$0.07(0.13%)
Day’s Range― - ―
52-Week Range$38.51 - $85.25
Previous CloseN/A
Volume127.14K
Average Volume (3M)462.80K
Market Cap
$3.09B
Enterprise Value$3.05B
Total Cash (Recent Filing)$417.27M
Total Debt (Recent Filing)$93.64M
Price to Earnings (P/E)―
Beta0.33
Next Earnings
May 12, 2026EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding42,557,490
10 Day Avg. Volume389,480
30 Day Avg. Volume462,797
Financial Highlights & Ratios
PEG Ratio1.07
Price to Book (P/B)9.96
Price to Sales (P/S)7.58
P/FCF Ratio-153.35
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue6.76
Enterprise Value/Gross Profit7.55
Enterprise Value/Ebitda-54.61
Forecast
1Y Price Target
$89.67Price Target Upside21.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-0.71
Revenue Forecast (FY)$693.25M
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentFirst patient dosing in the Phase 2 study for TP-05 moves the program into a larger randomized trial that could validate earlier proof-of-concept tick-killing results and support clinical advancement.
Commercial TractionStrong XDEMVY launch, marked by substantial product shipments and broad payer coverage, indicates growing adoption among eye care providers and meaningful revenue potential.
Partner CollaborationRegulatory approval in Greater China and the associated partner milestone demonstrate regulatory validation and create additional regional revenue streams through partner-led commercialization.
Bears Say
International Execution RiskRegulatory uncertainty and variable prescriber receptivity outside the United States increase the risk that international expansion will not deliver anticipated sales growth.
Revenue And Profitability PressureHigh gross-to-net discounts materially reduce net revenues and represent a sustained headwind to profitability and operating leverage.
Valuation UncertaintyAnalyst exclusion of TP-05 from company valuation signals uncertainty about its contribution to reported value and may cap investor expectations until clinical results are incorporated.
Tarsus Pharmaceuticals News
TARS FAQ
What was Tarsus Pharmaceuticals’s price range in the past 12 months?
Tarsus Pharmaceuticals lowest stock price was $38.51 and its highest was $85.25 in the past 12 months.
What is Tarsus Pharmaceuticals’s market cap?
Tarsus Pharmaceuticals’s market cap is $3.09B.
When is Tarsus Pharmaceuticals’s upcoming earnings report date?
Tarsus Pharmaceuticals’s upcoming earnings report date is May 12, 2026 which is in 27 days.
How were Tarsus Pharmaceuticals’s earnings last quarter?
Tarsus Pharmaceuticals released its earnings results on Feb 23, 2026. The company reported -$0.2 earnings per share for the quarter, missing the consensus estimate of -$0.093 by -$0.107.
Is Tarsus Pharmaceuticals overvalued?
According to Wall Street analysts Tarsus Pharmaceuticals’s price is currently Undervalued.
Does Tarsus Pharmaceuticals pay dividends?
Tarsus Pharmaceuticals does not currently pay dividends.
What is Tarsus Pharmaceuticals’s EPS estimate?
Tarsus Pharmaceuticals’s EPS estimate is -0.32.
How many shares outstanding does Tarsus Pharmaceuticals have?
Tarsus Pharmaceuticals has 42,557,490 shares outstanding.
What happened to Tarsus Pharmaceuticals’s price movement after its last earnings report?
Tarsus Pharmaceuticals reported an EPS of -$0.2 in its last earnings report, missing expectations of -$0.093. Following the earnings report the stock price went up 7.788%.
Which hedge fund is a major shareholder of Tarsus Pharmaceuticals?
Currently, no hedge funds are holding shares in TARS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tarsus Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$89.67 (21.49% Upside)
$89.67 (21.49% Upside)
Blogger Sentiment
Bullish
TARS Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 126.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $6.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.4%
Last 30 Days ▲ 10.9%
Last 30 Days ▲ 10.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
56.47%
12-Months-Change
Fundamentals
Return on Equity
-19.63%
Trailing 12-Months
Asset Growth
50.23%
Trailing 12-Months
Company Description
Tarsus Pharmaceuticals
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
TARS Company Deck
TARS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated a strongly positive commercial trajectory for XDEMVY—robust 2025 performance, bold 2026 guidance (+~50% at midpoint), expanding awareness and payer coverage, product-line profitability, and a funded pipeline with near-term clinical catalysts for TP-04 and TP-05. Offsetting these positives are material near-term expense levels, a high gross-to-net discount (~43%-45%), Q1 seasonality headwinds and reliance on new-patient driven growth until refill rates stabilize. Overall, the company presents clear growth momentum but must demonstrate operating leverage and sustained margin conversion to fully realize its $2B+ peak sales ambition.View all TARS earnings summariesTARS Stock 12 Month Forecast
Average Price Target
$89.67
▲(21.49% Upside)
Technical Analysis
Denali Therapeutics
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Disc Medicine
―
Recursion Pharmaceuticals
―
Ownership Overview
3.27% Insiders
23.59% Mutual Funds
50.41% Other Institutional Investors
10.45% Public Companies and
Individual Investors